[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

Sarah R Verhoeff, Sjoukje F Oosting, Sjoerd G Elias, Suzanne C van Es, Sophie L Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M E Desar, C Willemien Menke-van der Houven van Oordt, Astrid A M van der Veldt, Anne I J Arens, Adrienne H Brouwers, Bertha Eisses, Peter F A Mulders, Otto S Hoekstra, Gerben J C Zwezerijnen, Winette T A van der Graaf, Erik H J G Aarntzen, Wim J G Oyen, Carla M L van Herpen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

10 Citations (Scopus)
14 Downloads (Pure)


Purpose: Watchful waiting (WW) can be considered for patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis, especially those with <2 International Metastatic RCC Database Consortium criteria and ≤2 metastatic sites [referred to as watch and wait (“W&W”) criteria]. The IMaging PAtients for Cancer drug SelecTion-Renal Cell Carcinoma study objective was to assess the predictive value of [ 18F]FDG PET/CT and [ 89Zr]Zr-DFO-girentuximab PET/CT for WW duration in patients with mccRCC. Experimental Design: Between February 2015 and March 2018, 48 patients were enrolled, including 40 evaluable patients with good (n ¼ 14) and intermediate (n ¼ 26) prognosis. Baseline contrast-enhanced CT, [ 18F]FDG and [ 89Zr]Zr-DFO-girentuximab PET/CT were performed. Primary endpoint was the time to disease progression warranting systemic treatment. Maximum standardized uptake values (SUV max) were measured using lesions on CT images coregistered to PET/CT.

on the basis of median geometric mean SUV max of RECIST-measurable lesions across patients. Results: The median WW time was 16.1 months [95% confidence interval (CI): 9.0–31.7]. The median WW period was shorter in patients with high [ 18F]FDG tumor uptake than those with low uptake (9.0 vs. 36.2 months; HR, 5.6; 95% CI: 2.4–14.7; P < 0.001). Patients with high [ 89Zr]Zr-DFO-girentuximab tumor uptake had a median WW period of 9.3 versus 21.3 months with low uptake (HR, 1.7; 95% CI: 0.9–3.3; P ¼ 0.13). Patients with “W&W criteria” had a longer median WW period of 21.3 compared with patients without: 9.3 months (HR, 1.9; 95% CI: 0.9–3.9; P one-sided ¼ 0.034). Adding [ 18F]FDG uptake to the “W&W criteria” improved the prediction of WW duration (P < 0.001); whereas [ 89Zr]Zr-DFO-girentuximab did not (P ¼ 0.53). Conclusions: In patients with good- or intermediate-risk mccRCC, low [ 18F]FDG uptake is associated with prolonged WW. This study shows the predictive value of the “W&W criteria” for WW duration and shows the potential of [ 18F]FDG-PET/CT to further improve this.

Original languageEnglish
Pages (from-to)592-601
Number of pages10
JournalClinical Cancer Research : an official journal of the American Association for Cancer Research
Issue number3
Publication statusPublished - 1 Feb 2023

Bibliographical note

Publisher Copyright:
© 2023 American Association for Cancer Research Inc.. All rights reserved.


Dive into the research topics of '[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this